Core Viewpoint - The company, Huaguang New Materials, is planning to issue shares to specific investors through a simplified procedure, which may dilute immediate returns for existing shareholders. The company has outlined measures to mitigate this dilution risk and has made commitments from relevant parties to ensure these measures are effectively implemented [1][2][12]. Financial Impact Analysis - Before the issuance, the total share capital of the company is 90,085,520 shares. The maximum amount to be raised through this issuance is capped at 199 million yuan. Post-issuance, the total share capital will increase, and while the net asset scale will also rise, the short-term economic benefits from the raised funds may lag, leading to a dilution of earnings per share [2][5]. - The company has provided three scenarios for the projected net profit for 2025 compared to 2024: a 10% increase, no change, and a 10% decrease. The diluted earnings per share under these scenarios are projected to be 0.92 yuan, 0.83 yuan, and 0.75 yuan respectively [5][6]. Measures to Mitigate Dilution Risk - The company plans to strengthen the management of raised funds to ensure compliance and effective use. This includes special storage of the funds and strict adherence to investment plans [10]. - The company aims to expedite the preparation and implementation of the fundraising investment projects to achieve expected benefits sooner, thereby enhancing its sustainable profitability [10]. - The governance structure will be improved to ensure that shareholders can exercise their rights effectively, and the board will make informed decisions to protect shareholder interests [10][11]. Commitment from Management - The company's board and senior management have made commitments to ensure the execution of measures to mitigate the dilution of immediate returns. They have pledged to adhere to relevant regulations and to compensate for any losses incurred due to non-compliance with these commitments [12].

Group 1 - The company held its 15th meeting of the 8th Board of Directors on June 6, 2025, with all 6 directors present, ensuring compliance with relevant laws and regulations [1] - The Board approved a proposal to change part of the fundraising investment projects for convertible bonds, which will be submitted to the shareholders' meeting and the bondholders' meeting for review [2][3] - The Board agreed to hold the second extraordinary shareholders' meeting on June 24, 2025, using a combination of on-site and online voting [2] - The Board also approved the proposal to convene the first bondholders' meeting for "Rong 23 Convertible Bonds" on June 24, 2025 [3]

Core Viewpoint - The company has adjusted the internal investment structure of its fundraising projects based on actual progress and future planning, ensuring that it does not negatively impact normal operations or shareholder interests [1][2]. Group 1 - The fifth Supervisory Board meeting of the company was held on May 30, 2025, with all three supervisors present, and the meeting was conducted in accordance with relevant laws and regulations [1]. - The Supervisory Board approved the proposal to adjust the internal investment structure of fundraising projects, confirming that the adjustments align with the company's actual situation [1]. - The adjustments made do not constitute a disguised change in the use of raised funds or harm shareholder interests, complying with regulatory requirements [1]. Group 2 - The voting results for the proposal were unanimous, with 3 votes in favor, 0 against, and 0 abstentions, indicating strong support from the Supervisory Board [2]. - The proposal will be submitted for review at the shareholders' meeting, indicating the next step in the decision-making process [2].

一、可转换公司债券募集资金基本情况 （一）可转换公司债券实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于同意浙江东亚药业股份有限公司向不特 定对象发行可转换公司债券注册的批复》 证券代码：605177 证券简称：东亚药业 公告编号：2025-029 债券代码：111015 债券简称：东亚转债 浙江东亚药业股份有限公司 关于可转换公司债券募集资金投资项目延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 第四届董事会第八次会议、第四届监事会第七次会议，分别审议通过了《关于可 转换公司债券募集资金投资项目延期的议案》，主要内容如下： 年 7 月 12 日全部到账，并经中汇会计师事务所（特殊普通合伙）审验，于 2023 年 7 月 12 日出具了《债券募集资金到位情况验证报告》 （中汇会验20238458 号）。 （二）可转换公司债券募集资金投资项目的情况 截至 2024 年 12 月 31 日，根据《浙江东亚药业股份有限公司向不特定对象 发行可转换公司债券募集说明书》，公司可转换公司债券募集资金投资项目及募 ...

Summary of Key Points Core Viewpoint - The company, Shaanxi Beiyuan Chemical Group Co., Ltd., has decided to adjust the implementation schedule of its fundraising investment projects due to objective factors such as macroeconomic conditions and industry cycle fluctuations, while ensuring that the project content, investment total, and scale remain unchanged [1][11][12]. Group 1: Fundraising Overview - The company approved the public offering of up to 361,111,112 new shares, with total fundraising amounting to 343,999.07 million yuan [1][2]. - As of December 31, 2024, the actual use of the raised funds is 102,829.73 million yuan [4][10]. Group 2: Project Delay Details - The completion dates for several projects, including the 120,000 tons/year glycine project and the intelligent factory basic platform construction, have been extended to June 2025 due to various delays [6][10]. - The company plans to further adjust the completion dates for several projects to June 2027, including the 100,000 tons/year CPE and 20,000 tons/year CPVC projects [6][10]. Group 3: Reasons for Delay - The glycine project is delayed due to the immature industrial production setup of the mixed solvent method and the need for further testing and equipment selection [7][10]. - The intelligent factory project is affected by the need for system optimization and compliance with safety standards [8][10]. - The salt production project faces market challenges due to limited demand and economic viability [9][10]. Group 4: Measures to Ensure Completion - The company is actively working on plans to utilize by-products from the glycine project and is optimizing project management to ensure timely completion [7][8]. - Detailed optimization plans and strategies are being developed to ensure the intelligent factory project progresses smoothly [8][10]. - The company is conducting thorough market analysis and technical research to validate the feasibility of the salt production project [9][10]. Group 5: Impact of Project Delay - The delay in fundraising investment projects is based on careful consideration of objective circumstances and does not involve changes to project implementation subjects, fundraising purposes, or investment scales, thus not adversely affecting the company's operations or shareholder interests [10][11].

民生证券股份有限公司 关于深圳市景旺电子股份有限公司 募投项目延期的核查意见 民生证券股份有限公司（以下简称"民生证券"或"保荐机构"）作为深圳 市景旺电子股份有限公司（以下简称"景旺电子"或"公司"）2023 年公开发行 可转换公司债券的保荐机构，根据《证券发行上市保荐业务管理办法》《上市公 司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上海证券交 易所股票上市规则》和《上海证券交易所上市公司自律监管指引第 1 号——规范 运作》等相关规定，就景旺电子本次募投项目延期事项进行了审慎核查，核查情 况如下： 一、募集资金的基本情况 经中国证券监督管理委员会《关于核准深圳市景旺电子股份有限公司公开发 行可转换公司债券的批复》（证监许可2023127 号）核准，公司于 2023 年 4 月 4 日向社会公众公开发行可转换公司债券（以下简称"景 23 转债"）1,154.00 万张，每张面值 100 元，募集资金总额为人民币 115,400.00 万元，扣除发行费 用人民币 1,438.46 万元，募集资金净额为 113,961.54 万元。上述募集资金已于 殊普通合伙）审验并出具了天职业字2023 ...

证券代码：688189 证券简称：南新制药 公告编号：2025-022 湖南南新制药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 公司首次公开发行人民币普通股 3,500 万股，发行价格为 34.94 元/股，募 集资金总额为人民币 122,290.00 万元，扣除发行费用合计人民币 8,761.77 万元 （不含增值税）后，实际募集资金净额为人民币 113,528.23 万元。上述募集资 金已于 2020 年 3 月 20 日全部到位，由天职国际会计师事务所（特殊普通合伙） 对本次发行募集资金的到账情况进行了审验，并出具了（天职业字202016008 号）《验资报告》。 湖南南新制药股份有限公司（以下简称"公司"）于 2025 年 5 月 23 日召开 第二届董事会第十六次会议和第二届监事会第十四次会议，审议通过了《关于公 司部分募集资金投资项目延期的议案》，同意公司对募投项目"营销渠道网络升 级建设项目"达到预定可使用状态的时间进行调整。 根据有关法律、法规及《上海证券交易所科创板上市公司自律监管指引第 ...

Core Points - The company announced a board and supervisory meeting on May 21, 2025, to approve the extension of certain fundraising investment projects and the addition of implementation entities and locations [1] - The "Annual Production of 60,000 Riding Lawn Mowers Project" deadline has been extended to August 31, 2027, with the addition of Daye Mexico Sociedad Anonima de Capital Variable as a co-implementing entity and Mexico as a new implementation location [1] - As of December 31, 2024, the project has accumulated an investment of 101 million yuan, with an investment progress of 45.75% [1] - The adjustments made do not involve changes in the use of raised funds and will not have a significant adverse impact on the company's normal production and operations [1]

证券代码：603117 证券简称：万林物流 公告编号：2025-018 江苏万林现代物流股份有限公司 关于2024年年度股东大会增加临时提案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 股东大会有关情况 | 股份类别 | 股票代码 | 股票简称 | 股权登记日 | | --- | --- | --- | --- | | Ａ股 | 603117 | 万林物流 | 2025/5/22 | 二、 增加临时提案的情况说明 公司已于2025 年 4 月 29 日公告了股东大会召开通知，单独持有15.57%股 份的控股股东共青城苏瑞投资有限公司，在2025 年 5 月 15 日提出临时提案并 书面提交股东大会召集人。股东大会召集人按照《上市公司股东大会规则》有关 规定，现予以公告。 公司于 2025 年 5 月 15 日召开了第五届董事会第二十五次会议、第五届监事 会第十七次会议，审议通过《关于募集资金投资项目结项及终止并将节余募集资 金永久补充流动资金的议案》，上述议案尚需提交股东大会审议。 公司控股股东共青城苏瑞投资有 ...

证券代码：000876 证券简称：新希望 公告编号：2025-49 登录新浪财经APP 搜索【信披】查看更多考评等级 债券代码：127015,127049 债券简称：希望转债，希望转2 新希望六和股份有限公司关于部分募集资金投资项目结项的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 新希望六和股份有限公司（以下简称"公司"或"新希望"） 2020年9月非公开发行股票及2021年11月公开 发行可转换公司债券部分募集资金投资项目（以下简称"募投项目"）已实施完毕，达到预定可使用状 态，公司对该部分募投项目进行结项。现将相关情况公告如下： 一、募集资金基本情况 （一）2020年9月非公开发行股票 根据中国证监会《关于核准新希望六和股份有限公司非公开发行股票的批复》（证监许可[2020]1961 号）核准，公司向南方希望实业有限公司、新希望集团有限公司两位特定股东非公开发行人民币普通股 177,147,918股，每股发行价人民币22.58元，募集资金总额人民币3,999,999,988.44元，扣除各项发行费 用5,249,523.75元后，实际募集资金净额 ...